Article
Investigation of FANCD2 in triple negative breast cancer
2019-01-01
Abstract excerpt
Despite triple negative breast cancer (TNBC) representing between 10 % to 15 % of all breast cancers, no important therapeutic advances have been developed since the introduction of taxanes as an adjuvant therapy over 20 years ago. In order to develop novel therapies for TNBC patients, a thorough understanding of the vulnerability of components of the DNA damage response (DDR), involved in the survival and progres...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0fe4461c-27eb-56bf-bbe8-65ce78e8049d
- DOI
- 10.17638/03046847
